Показано 0 из 0
Дата |
---|
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
18.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
8.82
|
8.82
|
8.96
|
8.84
|
|
|
|
|
|
|
8.88
|
8.88
|
9.06
|
8.94
|
|
|
|
|
|
|
8.54
|
8.54
|
9.08
|
9.00
|
|
|
|
|
|
|
8.36
|
8.36
|
8.66
|
8.66
|
|
|
|
|
|
|
8.34
|
8.34
|
8.48
|
8.48
|
|
|
|
|
|
|
8.36
|
8.36
|
8.46
|
8.44
|
|
|
|
|
|
|
8.34
|
8.34
|
8.46
|
8.46
|
|
|
|
|
|
|
8.30
|
8.30
|
8.40
|
8.40
|
|
|
|
|
|
|
8.48
|
8.48
|
8.70
|
8.70
|
|
|
|
|
|
|
8.40
|
8.40
|
8.60
|
8.60
|
|
|
|
|
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase II (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase Ib (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).